What Diseases Have Cures? A Look at Curable Conditions

Dozens of diseases and medical conditions are genuinely curable today, from common bacterial infections knocked out by a course of antibiotics to hepatitis C, which can be eliminated from the body in as little as eight weeks. Certain cancers, most nutrient deficiencies, many parasitic infections, and even a small number of genetic disorders now have treatments that aim for full resolution rather than lifelong management. The list keeps growing, but the word “cure” means different things depending on the disease, and knowing where a condition falls on the spectrum between fully curable and merely treatable changes what you can realistically expect from medicine.

What Doctors Actually Mean by “Cured”

In everyday conversation, “cured” means the disease is gone for good. In medicine, the definition is more cautious. For many conditions, doctors prefer terms like “remission” or “sustained response” because proving that a disease will never return is surprisingly difficult. An expert panel addressing diabetes, for instance, defined a “cure” as the complete restoration of normal function maintained indefinitely without any medication, but acknowledged that proving permanence for any individual patient is essentially impossible.

The distinction matters in autoimmune diseases too. Researchers studying conditions like lupus and rheumatoid arthritis have proposed defining a cure as resolution of the disease without ongoing immunosuppressive therapy.¹ That sets a high bar: if you still need daily pills to keep your immune system from attacking your own tissues, you are in managed remission, not cured. This framework helps explain why some conditions that people casually call “curable” are more accurately described as controllable, and why others that sound incurable have genuinely curative treatments if you catch them early enough.

Bacterial Infections

The most straightforward cures in medicine are antibiotic treatments for bacterial infections. Strep throat, urinary tract infections, bacterial pneumonia, skin infections, and many sexually transmitted infections like chlamydia and gonorrhea are routinely cured with the right antibiotic. The bacteria are killed or suppressed below the level where they can sustain an infection, and the body clears the rest. For most common bacterial infections, this process takes days to a couple of weeks.

There has been a push in recent years to shorten antibiotic courses without sacrificing effectiveness. A large systematic review of clinical trials comparing shorter and longer treatment durations found that roughly 85% of the trials showed equivalent outcomes between short and long courses.² The old advice to “always finish the full course even if you feel better” is being reevaluated for many infections, though the specifics depend on the type and severity.

Tuberculosis is a bacterial infection that is curable but demands a longer, more complex regimen. The standard treatment is a six-month course that combines multiple drugs, typically starting with isoniazid, rifampin, and pyrazinamide for the first two months, then continuing with isoniazid and rifampin for four more.³ The treatment works well when patients can adhere to it, which is one of the central challenges in TB control worldwide. Drug-resistant strains complicate matters further, requiring longer courses with second-line drugs that have more side effects.

Hepatitis C, the Virus We Learned to Cure

For most of medical history, viral infections were things you either survived and cleared naturally, prevented with vaccines, or managed with antiviral drugs that kept the virus in check without eliminating it. Hepatitis C broke that pattern. Beginning around 2014, a new class of medications called direct-acting antivirals transformed hepatitis C from a chronic, liver-destroying infection into one of the most reliably curable serious diseases in medicine.

These drugs target specific steps in the virus’s life cycle and can cure hepatitis C in more than 95% of patients after just eight to twelve weeks of oral treatment.⁴ Real-world data from clinical settings, not just controlled trials, backs this up. A study across two large university medical centers in Brazil found an overall sustained virological response of about 97% in patients who completed treatment.⁵ “Sustained virological response” in hepatitis C is effectively synonymous with cure: the virus becomes undetectable and stays that way.

The hepatitis C story is one of medicine’s clearest recent victories. The challenge that remains is access. Many people with chronic hepatitis C worldwide are undiagnosed or unable to afford treatment, so a disease that is medically curable continues to cause liver failure and death largely because of gaps in screening and drug availability.

Cancers Where Treatment Is Curative

Cancer is not one disease, and saying “cancer is curable” or “cancer is incurable” is equally misleading. Some cancers respond so well to existing treatments that the expected outcome is a cure, even when the disease has already spread. Testicular cancer, gestational choriocarcinoma, Hodgkin lymphoma, and several high-grade non-Hodgkin lymphomas are routinely cured with chemotherapy.⁶ For Hodgkin lymphoma specifically, combination treatment cures roughly 80% to 90% of patients.⁷

Many other cancers are curable when caught early. Localized breast cancer, colon cancer, prostate cancer, melanoma, and thyroid cancer all have high long-term survival rates when surgically removed before spreading. The general pattern is that cancers detected at stage one or two have dramatically better outcomes than those found at stage three or four, though the specifics vary enormously by cancer type.

Newer therapies are expanding what is curable. CAR T-cell therapy, which reprograms a patient’s own immune cells to attack cancer, has shown striking results in blood cancers like acute lymphoblastic leukemia. In early trials, durable remission was achieved with an overall survival rate of about 78% at two years for patients who had relapsed or were resistant to other treatments.⁸ These are patients who had run out of conventional options, which makes the results especially significant. Whether CAR T-cell therapy will eventually be used more broadly, and whether its remissions will hold up over decades, are active areas of research.

Nutrient Deficiencies and Parasitic Diseases

Some of the most straightforwardly curable conditions are also the least glamorous. Scurvy, caused by vitamin C deficiency, is completely treatable and preventable with supplementation.⁹ The same principle applies to rickets (vitamin D deficiency), pellagra (niacin deficiency), beriberi (thiamine deficiency), and iron-deficiency anemia. Supply the missing nutrient, and the disease resolves. These conditions still appear in populations with limited food access, in people with severe eating disorders, and occasionally in older adults living alone with very restricted diets.

Parasitic infections represent another large category of curable diseases, though they receive less attention in wealthier countries. Malaria, when caused by most Plasmodium species, is curable with antimalarial drugs if treated promptly. Intestinal worms like hookworm, roundworm, and whipworm are cleared by standard deworming medications. Lymphatic filariasis, the parasitic disease that can cause dramatic swelling of limbs, has been targeted with a triple-drug regimen that cleared the parasites from the blood in about 96% of participants at follow-up periods extending to three years.¹⁰ Though existing tissue damage from long-standing infection may not reverse, eliminating the active infection halts progression.

Gene Therapy for Genetic Diseases

Until recently, genetic diseases were almost by definition incurable. If the problem was written into your DNA, the best medicine could offer was managing symptoms. That changed in 2023 when the FDA approved Casgevy, the first therapy based on CRISPR gene-editing technology, for sickle cell disease in patients aged twelve and older.¹¹ The treatment works by editing a patient’s own blood stem cells to boost production of fetal hemoglobin, which counteracts the sickling of red blood cells that defines the disease.

The approach involves removing a patient’s stem cells, editing them in the lab, and transplanting the modified cells back. In clinical trials, patients with sickle cell disease who received this treatment saw their painful vaso-occlusive crises either dramatically reduced or eliminated entirely, and patients with transfusion-dependent beta-thalassemia achieved transfusion independence.¹² CRISPR-based editing of stem cells could provide a permanent correction applicable to all patients regardless of whether a matched donor is available, which has been a major bottleneck for bone marrow transplant, the previous curative option.¹³

Gene therapy is also being developed or approved for spinal muscular atrophy, certain inherited retinal diseases, and some forms of hemophilia. These treatments are among the most expensive in medicine, sometimes carrying price tags above a million dollars per patient, which raises difficult questions about who actually gets access to a cure that exists on paper.

The Handful of People Cured of HIV

HIV remains incurable for the vast majority of the roughly 39 million people living with it. Antiretroviral therapy suppresses the virus to undetectable levels and allows a near-normal lifespan, but stopping treatment causes the virus to rebound from reservoirs hidden in the body. A true cure, where HIV is completely eliminated, has so far been confirmed in only a handful of people, all of whom received stem cell transplants for blood cancers they also had.

The best-known cases are the Berlin patient and the London patient, both of whom received transplants from donors carrying a rare double mutation in the CCR5 gene that makes cells resistant to HIV. More recent cases have expanded what seemed possible. One patient achieved long-term remission five years after a stem cell transplant from a sibling donor with the same double CCR5 mutation; follow-up showed no detectable intact HIV in blood or gut tissue.¹⁴ Even more intriguing, another patient achieved durable remission after a transplant from a donor who carried only one copy of the mutation, not two, suggesting the donor pool for potential HIV cures could be wider than originally thought.¹⁵

Stem cell transplantation remains the only approach with confirmed cases of HIV cure.¹⁶ But it is a dangerous, grueling procedure typically reserved for patients who need it for cancer treatment anyway. It is not a scalable solution. Researchers are studying gene therapy, broadly neutralizing antibodies, and “shock and kill” strategies aimed at flushing the virus from its hiding places. For now, HIV sits in an unusual position: curable in principle, as proven by a few extraordinary cases, but not yet curable in practice for most people.

Conditions Still Stuck Between Cure and Management

Autoimmune diseases illustrate the frustrating gap between effective treatment and genuine cure. Conditions like type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease can often be well controlled with immunosuppressive drugs, but stopping those drugs usually triggers a relapse. Researchers have argued that remission requiring ongoing immunosuppression should not be confused with a cure, since the underlying immune dysfunction persists.¹ Experimental approaches like autologous stem cell transplants and targeted B-cell depletion have produced drug-free remissions in some patients with lupus and multiple sclerosis, but these remain early-stage findings rather than standard treatments.

Mental health conditions occupy a similar space. Depression, anxiety disorders, and PTSD can be effectively treated with therapy and medication, and many people experience full resolution of symptoms. Cognitive-behavioral therapy programs designed for PTSD have shown significant improvements in symptoms and even loss of the PTSD diagnosis for treatment completers.¹⁷ A Cochrane review of psychological interventions for PTSD in people with severe mental illness found some evidence that trauma-focused cognitive-behavioral therapy could bring symptoms below the diagnostic threshold.¹⁸ Whether that constitutes a “cure” is a philosophical question as much as a medical one. Some people recover completely and never relapse; others need ongoing treatment to stay well.

When Existing Cures Stop Working

Having a cure does not guarantee it will keep working. Antimicrobial resistance is steadily eroding the effectiveness of antibiotics, antivirals, antifungals, and antiparasitic drugs. Multidrug resistance occurs when microorganisms develop the ability to withstand several antimicrobial agents, and it represents one of the most serious threats to modern healthcare.¹⁹ Drug-resistant tuberculosis, methicillin-resistant Staphylococcus aureus (MRSA), and drug-resistant gonorrhea are all examples of infections that were once straightforwardly curable and are now harder to treat, sometimes requiring last-resort drugs with significant side effects.

The drivers are well understood: overuse of antibiotics in human medicine, widespread use in agriculture, and patients not completing treatment courses all select for resistant bacteria. The pipeline of new antibiotics has slowed because developing them is expensive and less profitable than drugs for chronic conditions. This means some infections that were reliably curable a generation ago may eventually become untreatable if resistance trends continue unchecked.

Why Having a Cure Does Not Always Mean Getting One

The gap between a cure existing and a patient receiving it is one of the starkest inequities in global health. Hepatitis C is the clearest example: the drugs work in virtually everyone, but millions of infected people worldwide have no access to them. The problem is partly cost, partly infrastructure, and partly the absence of screening programs to identify who needs treatment.

Gene therapies and advanced cell therapies amplify this problem. These treatments can carry price tags of a million dollars or more per patient, which strains even wealthy healthcare systems and is effectively out of reach in lower-income countries. Payment models are being explored to make reimbursement sustainable, including outcomes-based agreements where the manufacturer is paid only if the treatment works, and installment plans that spread the cost over years.²⁰ But these are workarounds for a fundamental tension: curative therapies are most valuable precisely because they are one-time treatments, and the traditional insurance model of spreading recurring costs over time does not map cleanly onto a single expensive event.

Even for inexpensive cures, access can be a barrier. A costing study in Burkina Faso estimated that providing basic curative outpatient care to the poorest 20% of the population would require between roughly $2.8 million and $5.4 million per year at a low rate of healthcare contact, rising to $22 million to $43 million at a more adequate rate, consuming up to about 11% of the national healthcare budget.²¹ When the total consultation cost is a few dollars, the barrier is not the science. It is the infrastructure, the supply chain, and the political will to fund basic care for the people who need it most.

Conditions People Often Think Are Incurable but Are Not

A few diseases carry a reputation for being untreatable that they no longer deserve. Hepatitis C is the prime example, as covered above, but there are others. Early-stage cervical cancer caused by HPV is highly curable with surgery. Many skin cancers, including basal cell carcinoma and squamous cell carcinoma, are cured by excision alone. Peptic ulcers caused by Helicobacter pylori bacteria, once treated with a lifetime of acid-reducing medication, are now cured with a short course of antibiotics targeting the underlying infection.

Snakebite envenomation, while not a disease in the traditional sense, is another condition where effective treatment exists but awareness lags. Antivenoms can neutralize circulating venom when administered promptly. Research into improved antivenoms continues, including trivalent formulations designed to cover multiple snake species within a region.²² The challenge with snakebite, as with so many curable conditions, is getting the right treatment to the right person fast enough. Most snakebite deaths occur in rural areas far from hospitals that stock antivenom, making a curable emergency into a fatal one.

Smallpox deserves mention as the ultimate success story. It was not just curable but entirely eradicated through vaccination and a strategy of surveillance and containment led by the WHO beginning in 1966.²³ The program’s key insight was that smallpox spread relatively slowly, requiring prolonged face-to-face contact, which meant that isolating patients and vaccinating their contacts could break transmission chains even without vaccinating entire populations.²⁴ It remains the only human infectious disease to have been completely wiped out, a reminder that with the right disease characteristics and sufficient global coordination, even elimination is possible.